News & Events

A study in Nature co-authored by Tanja Stadler highlights how integrating AI into global health systems over the next five years could save lives by predicting disease outbreaks and improving healthcare resource allocation. The study emphasises the need for collaboration across academia, government, and industry to ensure AI is used ethically and effectively. While AI's potential is immense, experts caution that human oversight and high-quality data are crucial to avoid risks.

On 6 March, the next 'Bench meets Bedside' seminar organised by the Engineering Translational Medicine (ETM) initiative will take place on Campus Schällemätteli. Speakers include Judith Zaugg (UniBas) and Basile Wicky (ETH/D-BSSE), followed by short science talks from Luana Frias Guerra (UniBas) and Paweł Czyż (ETH Zürich). This seminar series builds a platform for researchers and clinicians to connect and collaborate.

Researchers around Martin Fussenegger from the Biotechnology Lab have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to the skin. One day, researchers want to use switches of this kind to trigger cell therapies for various metabolic diseases.

On 29 January, BioVersys launches its Initial Public Offering on the SIX Swiss Exchange. “Today marks the first step of us engaging with the public so that we may make the next clinical phase of developing BV100 and alpibectir and their eventual approval a reality,” says Marc Gitzinger, CEO and Co-Founder of BioVersys. BV100 and alpibectir are novel antimicrobial drug candidates targeting the most drug-resistant bacterial pathogens Acinetobacter baumannii and Mycobacterium tuberculosis.